GLIS2 and acute myeloid leukemia: Concordant with our study, Drenberg et al. previously reported a screen of 6568 unique compounds in 8 AML cell lines and revealed selective activity of JAK inhibitors for pediatric AMKL cell lines including those with CBFA2T3::GLIS2 fusion (44).